The period from 2005 to 2015 marked a surge in CD38 research, with keywords such as breast cancer, colorectal cancer, prostate cancer, apoptosis, hematopoietic stem cells, therapy and gene expression gaining attention. Here, CD38 is linked to prostate carcinoma.